Drugs / Oryz-Aspergillus Enzyme
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT04786795 Comparator | Mar 2021 → Feb 2022 | postcholecystectomy syndrome | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT07074379 Background | Jul 2025 → Dec 2027 expected | chronic pancreatitis | Changhai Hospital | Recruiting | No outcome recorded |
| — | NCT05261997 Background | Mar 2022 → Nov 2023 | chronic pancreatitis, exocrine pancreatic insufficiency | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oryz-aspergillus Enzyme | “Patients will use pancreatic enzymes (pancreatin enteric-coated capsules or oryz-aspergillus enzyme and pancreatin tablets) to control the symptoms of exocrine pancreatic insufficiency.” NCT07074379 ↗ |